% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{CastroEspin:294360,
      author       = {C. Castro-Espin and M. Cairat and A.-S. Navionis and C. C.
                      Dahm and C. S. Antoniussen and A. Tjønneland and L.
                      Mellemkjær and F. R. Mancini and M. Hajji-Louati and G.
                      Severi and C. Le Cornet$^*$ and R. Kaaks$^*$ and M. B.
                      Schulze and G. Masala and C. Agnoli and C. Sacerdote and M.
                      Crous-Bou and M.-J. Sánchez and P. Amiano and M.-D.
                      Chirlaque and M. Guevara and K. Smith-Byrne and A. K. Heath
                      and S. Christakoudi and M. J. Gunter and S. Rinaldi and A.
                      Agudo and L. Dossus},
      title        = {{P}rognostic role of pre-diagnostic circulating
                      inflammatory biomarkers in breast cancer survival: evidence
                      from the {EPIC} cohort study.},
      journal      = {British journal of cancer},
      volume       = {131},
      number       = {9},
      issn         = {0007-0920},
      address      = {Edinburgh},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2024-02193},
      pages        = {1496 - 1505},
      year         = {2024},
      abstract     = {Inflammation influences tumour progression and cancer
                      prognosis, but its role preceding breast cancer (BC) and its
                      prognostic implications remain inconclusive.We studied
                      pre-diagnostic plasma inflammatory biomarkers in 1538 women
                      with BC from the EPIC study. Cox proportional hazards models
                      assessed their relationship with all-cause and BC-specific
                      mortality, adjusting for tumour characteristics and
                      lifestyle factors.Over a 7-year follow-up after diagnosis,
                      229 women died, 163 from BC. Elevated IL-6 levels were
                      associated with increased all-cause mortality risk (HR1-SD
                      1.25, $95\%$ CI 1.07-1.47). Among postmenopausal, IL-6 was
                      associated with higher all-cause (HR1-SD 1.41, $95\%$ CI
                      1.18-1.69) and BC-specific mortality (HR1-SD 1.31, $95\%$ CI
                      1.03-1.66), (PHeterogeneity (pre/postmenopausal) < 0.05 for
                      both), while IL-10 and TNFα were associated with all-cause
                      mortality only (HR1-SD 1.19, $95\%$ CI 1.02-1.40 and HR1-SD
                      1.28, $95\%$ CI 1.06-1.56). Among ER+PR+, IL-10 was
                      associated with all-cause and BC-specific mortality (HR1-SD
                      1.35, $95\%$ CI 1.10-1.65 and HR1-SD 1.42 $95\%$ CI
                      1.08-1.86), while TNF-α was associated with all-cause
                      mortality in HER2- (HR1-SD 1.31, $95\%$ CI 1.07-1.61). An
                      inflammatory score predicted higher all-cause mortality,
                      especially in postmenopausal women (HR1-SD 1.30, $95\%$ CI
                      1.07-1.58).Higher pre-diagnosis IL-6 levels suggest poorer
                      long-term survival among BC survivors. In postmenopausal
                      survivors, elevated IL-6, IL-10, and TNFα and inflammatory
                      scores seem to predict all-cause mortality.},
      keywords     = {Humans / Female / Breast Neoplasms: mortality / Breast
                      Neoplasms: blood / Breast Neoplasms: diagnosis / Breast
                      Neoplasms: pathology / Middle Aged / Prognosis /
                      Inflammation: blood / Inflammation: mortality / Biomarkers,
                      Tumor: blood / Interleukin-6: blood / Aged / Postmenopause:
                      blood / Cohort Studies / Interleukin-10: blood / Adult /
                      Tumor Necrosis Factor-alpha: blood / Proportional Hazards
                      Models / Biomarkers, Tumor (NLM Chemicals) / Interleukin-6
                      (NLM Chemicals) / Interleukin-10 (NLM Chemicals) / Tumor
                      Necrosis Factor-alpha (NLM Chemicals) / IL6 protein, human
                      (NLM Chemicals) / IL10 protein, human (NLM Chemicals)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39342063},
      doi          = {10.1038/s41416-024-02858-6},
      url          = {https://inrepo02.dkfz.de/record/294360},
}